CDMO eXmoor Pharma and the Translational Research Office (TRO) at University College London (UCL) formed a strategic collaboration to speed the development of novel cell and gene therapies (CGTs) from academic research into clinical application.
The collaboration intends to support earlier and more efficient engagement between UCL innovators and eXmoor’s multidisciplinary teams, helping to reduce the risk, cost, and complexity of technology development. By combining the TRO’s translational research expertise with eXmoor’s consultancy, development and Good Manufacturing Practice (GMP) capabilities, the collaboration aims to create faster and more effective routes to clinical trial readiness and beyond, according to officials at both organizations.
Shared focus on strategic, scalable translation
UCL and eXmoor emphasize that they share a commitment to overcoming the technical and regulatory challenges that often delay promising CGT candidates. Through this relationship, academic teams will gain early access to:
- CMC consulting and regulatory strategy support
- Laboratory capacity and expertise in process and analytical development
- GMP manufacturing for early clinical studies
- Cross-modality insight across viral vectors, autologous and allogeneic cell therapies, and RNA technologies
UCL researchers say they will benefit from structured early engagement with eXmoor’s expert teams, which should help shape more practical and commercially aware development strategies. This includes opportunities for grant input, regular consultancy clinics, and joint events, all designed to bridge the gap between academic innovation and GMP readiness.
eXmoor expects to benefit from direct collaboration with UCL’s translational researchers, enabling its teams to take part in technological innovation and evolving CGT modalities. By working together from the earliest stages of development, eXmoor can align its capabilities with emerging innovations and foster scalable, GMP-ready solutions that reflect real clinical and commercial potential, explains Angela Osborne, founder and executive chair of eXmoor Pharma.
“The strength of the U.K.’s academic science has always been clear but getting groundbreaking therapies from the lab to patients requires a collaborative approach. This partnership with UCL TRO reflects our shared belief that supporting translational research with practical, GMP-ready solutions is the key to unlocking meaningful outcomes for patients,” she continues.
“UCL is committed to driving innovation that transforms lives, with a pipeline of Advanced Therapy Medicinal Products (ATMPs),” says Pamela Tranter, head of the Translational Research Group at the TRO. “Through this strategic partnership, we look forward to connecting UCL researchers with eXmoor’s expertise, supporting closer collaboration with industry and the development of practical, scalable plans that could help realize therapeutic potential.”
